Pharmaron Beijing Co., Ltd. (SHE:300759)

Market Cap	57.18B +38.3%
Revenue (ttm)	14.57B +14.7%
Net Income	1.69B -9.4%
EPS	0.95 -10.0%
Shares Out	1.84B
PE Ratio	35.75
Forward PE	26.62
Dividend	0.20 (0.65%)
Ex-Dividend Date	Jul 7, 2026

Volume	103,202,928
Open	29.38
Previous Close	30.98
Day's Range	29.38 - 34.90
52-Week Range	21.01 - 37.63
Beta	0.70
Analysts	Buy
Price Target	36.33 (+7.04%)
Earnings Date	Aug 21, 2026

About Pharmaron Beijing

Pharmaron Beijing Co., Ltd., together with its subsidiaries, operates as a pharmaceutical research and development service platform in North America, Europe, the Mainland China, Asia, and internationally. It operates through five segments: Laboratory Services; Chemical and Formulation Process Development and Manufacturing Services; Clinical Research Services; Macromolecule and Cell and Gene Therapy Services; and Others. The company offers laboratory chemistry and biological science services, including small molecule chemical drugs, oligonucleot...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2004
• Employees: 25,088
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 300759

Financial Performance

In 2025, Pharmaron Beijing's revenue was 14.10 billion, an increase of 14.82% compared to the previous year's 12.28 billion. Earnings were 1.66 billion, a decrease of -7.22%.

Analyst Summary

According to 12 analysts, the average rating for 300759 stock is "Buy." The 12-month stock price target is ¥36.33, which is an increase of 7.04% from the latest price.

Price Target

¥36.33

(7.04% upside)

Analyst Consensus: Buy

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Jul 10, 2026

Data Sources Report a data error